Clinical Research Directory

Inclusion Criteria: 1. Histologically confirmed malignant formation (ICD 10-11 codes С18, С19, С20, С34, С50, С61, С64). 2. 0-2 points on the WHO/ECOG scale of assessment of the general condition of the patient. 3. The absence of disease progression after the current line of chemotherapeutic treatment. 4. The number of oligometastases is not more than 3 in one organ, in the presence of a multi-organ lesion. 5. The total number of distant metastases is no more than 5. 6. Life expectancy of more than 6 months for brain metastases (GPA-score) 7. The possibility of SBRT for all distant metastases, in accordance with the criteria specified in the study design. 8. Making decisions on the inclusion of a patient in the study protocol based on the results of an interdisciplinary consultation consisting of an oncologist, a chemotherapist and a radiotherapist. 9. Signed informed consent Exclusion Criteria: 1. 3-4 points on the WHO/ECOG scale of assessment of the general condition of the patient 2. The complete response of all foci to the chemotherapy. 3. Distant metastases only in the brain, without damage to bones and other organs. 4. Brain metastasis of more than 3 cm in one dimension, requiring surgical treatment. 5. Distant metastasis in the brain stem and spinal cord. 6. The size of at least one distant metastasis is more than 5 cm. 7. Previously performed radiation therapy on one of the metastatic foci. 8. Metastatic lesion of the pleura, membranes of the brain or peritoneum. 9. The impossibility of CTT for all distant metastases, in accordance with the criteria specified in the study design. 10. Invasion into great vessels (aorta, carotid arteries, pulmonary arteries, etc.), organs of the digestive tract (esophagus, stomach, intestines), skin. 11. Compression of the spinal cord by distant metastasis according to instrumental studies.